Nov 18, 2020
Dr. Richard Furie discuss his recent involvement with the Phase
3 BLISS-LN clinical trial that is setting the stage for the first
ever FDA approved drug for lupus nephritis.
Dr. Furie is a professor at the Feinstein Institutes for medical
research, Northwell Health’s science arm of the health system.
Regarded as one the senior rheumatologists in the New York
metropolitan area, he has been on the Boards of Directors of the
local chapters of the Arthritis Foundation and the Lupus Alliance
of America and has been a member of the Medical-Scientific Advisory
Council of the Lupus Foundation of America as well as its Lupus
News editorial board. He also is on the Medical and Scientific
Advisory Board of the SLE Foundation as well as the Alliance for
Lupus Research Scientific Advisory Board.